A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This is a research study to find out if a drug called, osimertinib, is safe and effective in
treating advanced Non-Small Cell Lung Cancer (NSCLC) by targeting the treatment of epidermal
growth factor receptor (EGFR) mutation exon 18 G719X, exon 20 S7681, or exon 21 L861Q.
Patients on the study will not have had previous tyrosine kinase inhibitor (TKI) treatment.